SEARCH

SEARCH BY CITATION

References

  • Amin, H.M., Ergin, M., Denning, M.F., Quevedo, M.E. & Alkan, S. (2000) Characterization of apoptosis induced by protein kinase C inhibitors and its modulation by the caspase pathway in acute promyelocytic leukaemia. British Journal of Haematology, 110, 552562.
  • Argetsinger, L.S., Kouadio, J.L., Steen, H., Stensballe, A., Jensen, O.N. & Carter-Su, C. (2004) Autophosphorylation of JAK2 on tyrosines 221 and 570 regulates its activity. Molecular and Cellular Biology, 24, 49554967.
  • Benekli, M., Xia, Z., Donohue, K.A., Ford, L.A., Pixley, L.A., Baer, M.R., Baumann, H. & Wetzler, M. (2002) Constitutive activity of signal transducer and activator of transcription 3 protein in acute myeloid leukemia blasts is associated with short disease-free survival. Blood, 99, 252257.
  • Biethahn, S., Alves, F., Wilde, S., Hiddemann, W. & Spiekermann, K. (1999) Expression of granulocyte colony-stimulating factor- and granulocyte-macrophage colony-stimulating factor-associated signal transduction proteins of the JAK/STAT pathway in normal granulopoiesis and in blast cells of acute myelogenous leukemia. Experimental Hematology, 27, 885894.
  • Boggon, T.J., Li, Y., Manley, P.W. & Eck, M.J. (2005) Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog. Blood, 106, 9961002.
  • Bowman, T., Garcia, R., Turkson, J. & Jove, R. (2000) STATs in oncogenesis. Oncogene, 19, 24742488.
  • Delwel, R., Van Buitenen, C., Salem, M., Bot, F., Gillis, S., Kaushansky, K., Altrock, B. & Lowenberg, B. (1989) Interleukin-1 stimulates proliferation of acute myeloblastic leukemia cells by induction of granulocyte-macrophage colony-stimulating factor release. Blood, 74, 586593.
  • Feng, J., Witthuhn, B.A., Matsuda, T., Kohlhuber, F., Kerr, I.M. & Ihle, J.N. (1997) Activation of Jak2 catalytic activity requires phosphorylation of Y1007 in the kinase activation loop. Molecular and Cellular Biology, 17, 24972501.
  • Grandage, V.L., Gale, R.E., Linch, D.C. & Khwaja, A. (2005) PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kappaB, Mapkinase and p53 pathways. Leukemia, 19, 586594.
  • Gschwendt, M., Dieterich, S., Rennecke, J., Kittstein, W., Mueller, H.J. & Johannes, F.J. (1996) Inhibition of protein kinase C mu by various inhibitors. Differentiation from protein kinase c isoenzymes. FEBS Letters, 392, 7780.
  • Guiter, C., Dusanter-Fourt, I., Copie-Bergman, C., Boulland, M.L., Le Gouvello, S., Gaulard, P., Leroy, K. & Castellano, F. (2004) Constitutive STAT6 activation in primary mediastinal large B-cell lymphoma. Blood, 104, 543549.
  • Hayakawa, F., Towatari, M., Iida, H., Wakao, H., Kiyoi, H., Naoe, T. & Saito, H. (1998) Differential constitutive activation between STAT-related proteins and MAP kinase in primary acute myelogenous leukaemia. British Journal of Haematology, 101, 521528.
  • Hayakawa, F., Towatari, M., Kiyoi, H., Tanimoto, M., Kitamura, T., Saito, H. & Naoe, T. (2000) Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene, 19, 624631.
  • Iankov, I., Praskova, M., Kalenderova, S., Tencheva, Z., Mitov, I. & Mitev, V. (2002) The effect of chemical blockade of PKC with Go6976 and Go6983 on proliferation and MAPK activity in IL-6-dependent plasmacytoma cells. Leukemia Research, 26, 363368.
  • Ihle, J.N. (1995) The Janus protein tyrosine kinases in hematopoietic cytokine signaling. Seminars in Immunology, 7, 247254.
  • Ihle, J.N., Nosaka, T., Thierfelder, W., Quelle, F.W. & Shimoda, K. (1997) Jaks and Stats in cytokine signaling. Stem Cells, 15(Suppl. 1), 105111.
  • James, C., Ugo, V., Le Couedic, J.P., Staerk, J., Delhommeau, F., Lacout, C., Garcon, L., Raslova, H., Berger, R., Bennaceur-Griscelli, A., Villeval, J.L., Constantinescu, S.N., Casadevall, N. & Vainchenker, W. (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature, 434, 11441148.
  • Joos, S., Kupper, M., Ohl, S., Von Bonin, F., Mechtersheimer, G., Bentz, M., Marynen, P., Moller, P., Pfreundschuh, M., Trumper, L. & Lichter, P. (2000) Genomic imbalances including amplification of the tyrosine kinase gene JAK2 in CD30+ Hodgkin cells. Cancer Research, 60, 549552.
  • Kleinberger-Doron, N., Shelah, N., Capone, R., Gazit, A. & Levitzki, A. (1998) Inhibition of Cdk2 activation by selected tyrphostins causes cell cycle arrest at late G1 and S phase. Experimental Cell Research, 241, 340351.
  • Kurzer, J.H., Argetsinger, L.S., Zhou, Y.J., Kouadio, J.L., O'Shea, J.J. & Carter-Su, C. (2004) Tyrosine 813 is a site of JAK2 autophosphorylation critical for activation of JAK2 by SH2-B beta. Molecular and Cellular Biology, 24, 45574570.
  • Lacronique, V., Boureux, A., Monni, R., Dumon, S., Mauchauffe, M., Mayeux, P., Gouilleux, F., Berger, R., Gisselbrecht, S., Ghysdael, J. & Bernard, O.A. (2000) Transforming properties of chimeric TEL-JAK proteins in Ba/F3 cells. Blood, 95, 20762083.
  • Lawrence, D.S. & Niu, J. (1998) Protein kinase inhibitors: the tyrosine-specific protein kinases. Pharmacology and therapeutics, 77, 81114.
  • Levine, R.L., Wadleigh, M., Cools, J., Ebert, B.L., Wernig, G., Huntly, B.J., Boggon, T.J., Wlodarska, I., Clark, J.J., Moore, S., Adelsperger, J., Koo, S., Lee, J.C., Gabriel, S., Mercher, T., D'Andrea, A., Frohling, S., Dohner, K., Marynen, P., Vandenberghe, P., Mesa, R.A., Tefferi, A., Griffin, J.D., Eck, M.J., Sellers, W.R., Meyerson, M., Golub, T.R., Lee, S.J. & Gilliland, D.G. (2005a) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell, 7, 387397.
  • Levine, R.L., Loriaux, M., Huntly, B.J., Loh, M.L., Beran, M., Stoffregen, E., Berger, R., Clark, J.J., Willis, S.G., Nguyen, K.T., Flores, N.J., Estey, E., Gattermann, N., Armstrong, S., Look, A.T., Griffin, J.D., Bernard, O.A., Heinrich, M.C., Gilliland, D.G., Druker, B. & Deininger, M.W. (2005b) The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood, 106, 33773379.
  • Lucet, I.S., Fantino, E., Styles, M., Bamert, R., Patel, O., Broughton, S.E., Walter, M., Burns, C.J., Treutlein, H., Wilks, A.F. & Rossjohn, J. (2006) The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor. Blood, 107, 176183.
  • Malaviya, R. & Uckun, F.M. (1999) Genetic and biochemical evidence for a critical role of Janus kinase (JAK)-3 in mast cell-mediated type I hypersensitivity reactions. Biochemical and Biophysical Research Communications, 257, 807813.
  • Martinelli, G., Soverini, S., Rosti, G. & Baccarani, M. (2005) Dual tyrosine kinase inhibitors in chronic myeloid leukemia. Leukemia, 19, 18721879.
  • Martiny-Baron, G., Kazanietz, M.G., Mischak, H., Blumberg, P.M., Kochs, G., Hug, H., Marme, D. & Schachtele, C. (1993) Selective inhibition of protein kinase C isozymes by the indolocarbazole Go 6976. Journal of Biological Chemistry, 268, 91949197.
  • Matsuda, T., Feng, J., Witthuhn, B.A., Sekine, Y. & Ihle, J.N. (2004) Determination of the transphosphorylation sites of Jak2 kinase. Biochemical and Biophysical Research Communications, 325, 586594.
  • Meydan, N., Grunberger, T., Dadi, H., Shahar, M., Arpaia, E., Lapidot, Z., Leeder, J.S., Freedman, M., Cohen, A., Gazit, A., Levitzki, A. & Roifman, C.M. (1996) Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature, 379, 645648.
  • Murohashi, I., Tohda, S., Suzuki, T., Nagata, K., Yamashita, Y. & Nara, N. (1989) Autocrine growth mechanisms of the progenitors of blast cells in acute myeloblastic leukemia. Blood, 74, 3541.
  • Nagar, B., Bornmann, W.G., Pellicena, P., Schindler, T., Veach, D.R., Miller, W.T., Clarkson, B. & Kuriyan, J. (2002) Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Research, 62, 42364243.
  • O'Shea, J.J., Gadina, M. & Schreiber, R.D. (2002) Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell, 109(Suppl.), S121S131.
  • Peeters, P., Raynaud, S.D., Cools, J., Wlodarska, I., Grosgeorge, J., Philip, P., Monpoux, F., Van Rompaey, L., Baens, M., Van den, B.H. & Marynen, P. (1997) Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. Blood, 90, 25352540.
  • Pileri, S.A., Zinzani, P.L., Gaidano, G., Falini, B., Gaulard, P., Zucca, E., Sabattini, E., Ascani, S., Rossi, M. & Cavalli, F. (2003) Pathobiology of primary mediastinal B-cell lymphoma. Leukemia and Lymphoma, 44(Suppl. 3), S21S26.
  • Reiter, A., Walz, C., Watmore, A., Schoch, C., Blau, I., Schlegelberger, B., Berger, U., Telford, N., Aruliah, S., Yin, J.A., Vanstraelen, D., Barker, H.F., Taylor, P.C., O'Driscoll, A., Benedetti, F., Rudolph, C., Kolb, H.J., Hochhaus, A., Hehlmann, R., Chase, A. & Cross, N.C. (2005) The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2. Cancer Research, 65, 26622667.
  • Ruchatz, H., Coluccia, A.M., Stano, P., Marchesi, E. & Gambacorti-Passerini, C. (2003) Constitutive activation of Jak2 contributes to proliferation and resistance to apoptosis in NPM/ALK-transformed cells. Experimental Hematology, 31, 309315.
  • Savell, J., Ma, Y., Morrow, K.S., Jove, R., Olashaw, N., Moseley, P.L., Cress, W.D. & Wharton, W. (2004) AG490 inhibits G1-S traverse in BALB/c-3T3 cells following either mitogenic stimulation or exogenous expression of E2F-1. Molecular Cancer Therapeutics, 3, 205213.
  • Schuringa, J.J., Wierenga, A.T., Kruijer, W. & Vellenga, E. (2000) Constitutive Stat3, Tyr705, and Ser727 phosphorylation in acute myeloid leukemia cells caused by the autocrine secretion of interleukin-6. Blood, 95, 37653770.
  • Spiekermann, K., Biethahn, S., Wilde, S., Hiddemann, W. & Alves, F. (2001) Constitutive activation of STAT transcription factors in acute myelogenous leukemia. European Journal of Haematology, 67, 6371.
  • Steensma, D.P., Dewald, G.W., Lasho, T.L., Powell, H.L., McClure, R.F., Levine, R.L., Gilliland, D.G. & Tefferi, A. (2005) The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both ‘‘atypical’’ myeloproliferative disorders and the myelodysplastic syndrome. Blood, 106, 12071209.
  • Sternberg, D.W. & Gilliland, D.G. (2004) The role of signal transducer and activator of transcription factors in leukemogenesis. Journal of Clinical Oncology, 22, 361371.
  • Tefferi, A. & Gilliland, D.G. (2005) JAK2 in myeloproliferative disorders is not just another kinase. Cell Cycle, 4, 10531056.
  • Tefferi, A. & Spivak, J.L. (2005) Polycythemia vera: scientific advances and current practice. Seminars in Hematology, 42, 206220.
  • Thompson, J.E., Cubbon, R.M., Cummings, R.T., Wicker, L.S., Frankshun, R., Cunningham, B.R., Cameron, P.M., Meinke, P.T., Liverton, N., Weng, Y. & DeMartino, J.A. (2002) Photochemical preparation of a pyridone containing tetracycle: a Jak protein kinase inhibitor. Bioorganic Medicinal Chemistry Letters, 12, 12191223.
  • Wang, L.H., Kirken, R.A., Erwin, R.A., Yu, C.R. & Farrar, W.L. (1999) JAK3, STAT, and MAPK signaling pathways as novel molecular targets for the tyrphostin AG-490 regulation of IL-2-mediated T cell response. Journal of Immunology, 162, 38973904.
  • Ward, A.C., Touw, I. & Yoshimura, A. (2000) The Jak-Stat pathway in normal and perturbed hematopoiesis. Blood, 95, 1929.
  • Wong, S., McLaughlin, J., Cheng, D., Zhang, C., Shokat, K.M. & Witte, O.N. (2004) Sole BCR-ABL inhibition is insufficient to eliminate all myeloproliferative disorder cell populations. Proceedings of the National Academy of Sciences of the USA, 101, 1745617461.
  • Xia, Z., Baer, M.R., Block, A.W., Baumann, H. & Wetzler, M. (1998) Expression of signal transducers and activators of transcription proteins in acute myeloid leukemia blasts. Cancer Research, 58, 31733180.